Recent advances in Circulating Nucleic Acids in oncology
Standard
Recent advances in Circulating Nucleic Acids in oncology. / Otandault, A; Anker, P; Al Amir Dache, Z; Guillaumon, V; Meddeb, R; Pastor, B; Pisareva, E; Sanchez, C; Tanos, R; Tousch, G; Schwarzenbach, H; Thierry, A R.
In: ANN ONCOL, Vol. 30, No. 3, 01.03.2019, p. 374-384.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recent advances in Circulating Nucleic Acids in oncology
AU - Otandault, A
AU - Anker, P
AU - Al Amir Dache, Z
AU - Guillaumon, V
AU - Meddeb, R
AU - Pastor, B
AU - Pisareva, E
AU - Sanchez, C
AU - Tanos, R
AU - Tousch, G
AU - Schwarzenbach, H
AU - Thierry, A R
N1 - © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Circulating cell-free DNA (cfDNA) is one of the fastest growing and most exciting areas in oncology in recent years. Its potential clinical uses cover now each phase of cancer patient management care (predictive information, detection of the minimal residual disease, early detection of resistance, treatment monitoring, recurrence surveillance, and cancer early detection/screening). This review relates the recent advances in the application of circulating DNA or RNA in oncology building on unpublished or initial findings/work presented at the 10th international symposium on circulating nucleic acids in plasma and serum held in Montpellier from the 20th to the 22nd of September 2017. This year, presenters revealed their latest data and crucial observations notably in relation to (i) the circulating cell-free (cfDNA) structure and implications regarding their optimal detection; (ii) their role in the metastatic or immunological processes; (iii) evaluation of miRNA panels for cancer patient follow up; (iv) the detection of the minimal residual disease; (v) the evaluation of a screening tests for cancer using cfDNA analysis; and (vi) elements of preanalytical guidelines. This work reviews the recent progresses in the field brought to light in the meeting, as well as in the most important reports from the literature, past and present. It proposes a broader picture of the basic research and its potential, and of the implementation and current challenges in the use of circulating nucleic acids in oncology.
AB - Circulating cell-free DNA (cfDNA) is one of the fastest growing and most exciting areas in oncology in recent years. Its potential clinical uses cover now each phase of cancer patient management care (predictive information, detection of the minimal residual disease, early detection of resistance, treatment monitoring, recurrence surveillance, and cancer early detection/screening). This review relates the recent advances in the application of circulating DNA or RNA in oncology building on unpublished or initial findings/work presented at the 10th international symposium on circulating nucleic acids in plasma and serum held in Montpellier from the 20th to the 22nd of September 2017. This year, presenters revealed their latest data and crucial observations notably in relation to (i) the circulating cell-free (cfDNA) structure and implications regarding their optimal detection; (ii) their role in the metastatic or immunological processes; (iii) evaluation of miRNA panels for cancer patient follow up; (iv) the detection of the minimal residual disease; (v) the evaluation of a screening tests for cancer using cfDNA analysis; and (vi) elements of preanalytical guidelines. This work reviews the recent progresses in the field brought to light in the meeting, as well as in the most important reports from the literature, past and present. It proposes a broader picture of the basic research and its potential, and of the implementation and current challenges in the use of circulating nucleic acids in oncology.
KW - Journal Article
U2 - 10.1093/annonc/mdz031
DO - 10.1093/annonc/mdz031
M3 - SCORING: Review article
C2 - 30753271
VL - 30
SP - 374
EP - 384
JO - ANN ONCOL
JF - ANN ONCOL
SN - 0923-7534
IS - 3
ER -